ERBB2 and breast carcinoma: More recently, a study has targeted HER-2, a protein overexpressed in some breast cancers, using an antibody conjugated to a boron nitride nanotube/β-1,3-glucan-IgG complex (BNNT/β-glucan-IgG complex) [101].